Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china-Reference-Cited by-同舟云学术

Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china

Published:2017-04-13 Issue:11 Volume:58 Page:2758-2761
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Liu Haihui¹,Zhang Jingjing²,Ren Saisai¹,Chen Mingtai³,Liu Lulu³,Zhang Hao²

Affiliation:

1. Department of Graduate School, Jining Medical University, Jining, Shandong Province, China;

2. Department of Hematology, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China;

3. Department of Central Laboratory, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China

Funder

Science and Technology Program of Shandong Province, China

Health and Family Planning Commission of Shandong Province, China

Science and Technology Management Bureau of Jining City, China

Affiliated Hospital of Jining Medical University

Science and Technology Management Bureau of Jining City

Science and Technology Program of Shandong Province

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1312378

Reference15 articles.

1. Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia

2. The thorny issue of relapsed acute myeloid leukemia

3. Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study Group

4. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years;Hematology;2021-01-01

2. Cytarabine/granulocyte colony stimulating factors/omacetaxine mepesuccinate;Reactions Weekly;2017-09